Nothing Special   »   [go: up one dir, main page]

CY1117245T1 - Ενωσεις εναντι ογκων - Google Patents

Ενωσεις εναντι ογκων

Info

Publication number
CY1117245T1
CY1117245T1 CY20141100069T CY141100069T CY1117245T1 CY 1117245 T1 CY1117245 T1 CY 1117245T1 CY 20141100069 T CY20141100069 T CY 20141100069T CY 141100069 T CY141100069 T CY 141100069T CY 1117245 T1 CY1117245 T1 CY 1117245T1
Authority
CY
Cyprus
Prior art keywords
compounds against
against volume
volume
compounds
cancer
Prior art date
Application number
CY20141100069T
Other languages
English (en)
Inventor
Vicente Alberto Rodríguez
García-Ibarrola María Garranzo
Pérez Carmen Murcia
Sancho Francisco Sánchez
Marchante María Del Carmen Cuevas
Urbano Cristina Mateo
Juárez Isabel Digón
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of CY1117245T1 publication Critical patent/CY1117245T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Ένωση του γενικού τύπου (Ι), εις τον οποίο τα Α, Υ, W, R1, R2, R3, R4, R5 και R6 έχουν διάφορες έννοιες, για χρήση εις την θεραπευτική αγωγή του καρκίνου.
CY20141100069T 2007-12-20 2014-01-27 Ενωσεις εναντι ογκων CY1117245T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
EP08864895.1A EP2231633B1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (1)

Publication Number Publication Date
CY1117245T1 true CY1117245T1 (el) 2017-04-05

Family

ID=40580474

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100069T CY1117245T1 (el) 2007-12-20 2014-01-27 Ενωσεις εναντι ογκων

Country Status (27)

Country Link
US (4) US8710264B2 (el)
EP (3) EP2597091B1 (el)
JP (3) JP5727228B2 (el)
KR (3) KR101639772B1 (el)
CN (4) CN101903367B (el)
AT (1) ATE549313T1 (el)
AU (2) AU2008341670B2 (el)
BR (2) BRPI0821114B8 (el)
CA (2) CA2710087C (el)
CY (1) CY1117245T1 (el)
DK (2) DK2231590T3 (el)
ES (3) ES2578606T3 (el)
HK (3) HK1147998A1 (el)
HR (2) HRP20120464T1 (el)
IL (3) IL206396A (el)
MX (2) MX2010006795A (el)
MY (3) MY155342A (el)
NZ (3) NZ586012A (el)
PL (2) PL2231590T3 (el)
PT (2) PT2231590E (el)
RS (2) RS53140B (el)
RU (3) RU2528393C9 (el)
SG (2) SG170779A1 (el)
SI (2) SI2231590T1 (el)
UA (3) UA106967C2 (el)
WO (2) WO2009080761A1 (el)
ZA (3) ZA201004018B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2231590T3 (pl) 2007-12-20 2012-09-28 Pharma Mar Sa Związki przeciwnowotworowe
US9856196B2 (en) 2012-01-05 2018-01-02 Kao Corporation Agent for reduction of sensory irritation
CA2907832A1 (en) 2013-04-16 2014-10-23 Actelion Pharmaceuticals Ltd Antibacterial biaromatic derivatives
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質S−59917a及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
WO2000015634A2 (en) 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
WO2001074355A1 (en) * 2000-04-04 2001-10-11 Novartis Ag Method for treating cells resistant to antineoplastic agents
KR100868813B1 (ko) * 2002-03-04 2008-11-14 슬로안-케테링인스티튜트퍼캔서리서치 말단 분화의 유도 방법
MXPA06000975A (es) 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
US8324406B2 (en) 2006-06-16 2012-12-04 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
PL2231590T3 (pl) 2007-12-20 2012-09-28 Pharma Mar Sa Związki przeciwnowotworowe

Also Published As

Publication number Publication date
EP2231633B1 (en) 2013-10-30
PL2231633T3 (pl) 2014-03-31
RU2010130253A (ru) 2012-01-27
UA119963C2 (uk) 2019-09-10
HRP20140015T1 (hr) 2014-02-14
IL229594A (en) 2016-02-29
US20110034549A1 (en) 2011-02-10
SI2231590T1 (sl) 2012-10-30
WO2009080761A1 (en) 2009-07-02
CN102190643A (zh) 2011-09-21
RU2010130180A (ru) 2012-01-27
US9750759B2 (en) 2017-09-05
EP2231590B9 (en) 2012-08-15
HK1180678A1 (zh) 2013-10-25
EP2597091B1 (en) 2016-04-20
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
US20150344454A1 (en) 2015-12-03
BRPI0821114B1 (pt) 2021-09-08
JP2011506575A (ja) 2011-03-03
PT2231590E (pt) 2012-06-25
SG170779A1 (en) 2011-05-30
ES2578606T3 (es) 2016-07-28
RU2013112003A (ru) 2014-08-20
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
JP5727228B2 (ja) 2015-06-03
EP2597091A1 (en) 2013-05-29
MX2010006796A (es) 2010-10-26
RU2493147C2 (ru) 2013-09-20
UA106967C2 (uk) 2014-11-10
EP2231633A1 (en) 2010-09-29
AU2008341670A1 (en) 2009-07-02
JP2014133752A (ja) 2014-07-24
KR20100125226A (ko) 2010-11-30
IL206396A (en) 2014-05-28
MY148651A (en) 2013-05-15
EP2231590A1 (en) 2010-09-29
EP2231590B1 (en) 2012-03-14
MX2010006795A (es) 2010-10-26
CN101903337A (zh) 2010-12-01
US8710264B2 (en) 2014-04-29
BRPI0821116B1 (pt) 2020-02-18
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
JP5860088B2 (ja) 2016-02-16
IL206397A (en) 2014-01-30
SG170778A1 (en) 2011-05-30
AU2008341670B2 (en) 2012-04-19
DK2231633T3 (da) 2014-01-20
ZA201004017B (en) 2011-12-28
CN102174058A (zh) 2011-09-07
ZA201004018B (en) 2011-12-28
RU2528393C9 (ru) 2015-01-10
JP5529038B2 (ja) 2014-06-25
JP2011506578A (ja) 2011-03-03
NZ586013A (en) 2012-02-24
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
IL206397A0 (en) 2010-12-30
IL229594A0 (en) 2014-01-30
SI2231633T1 (sl) 2014-02-28
HK1147990A1 (en) 2011-08-26
IL206396A0 (en) 2010-12-30
CA2715203A1 (en) 2009-07-02
BRPI0821114A2 (pt) 2015-06-16
KR101541436B1 (ko) 2015-08-03
RS52343B (en) 2012-12-31
MY155342A (en) 2015-10-15
CA2715203C (en) 2015-09-08
HK1147998A1 (en) 2011-08-26
CN102190643B (zh) 2015-02-25
CN101903367A (zh) 2010-12-01
KR101639772B1 (ko) 2016-07-15
ES2442140T3 (es) 2014-02-25
HRP20120464T1 (hr) 2012-07-31
DK2231590T3 (da) 2012-07-09
ES2384420T3 (es) 2012-07-04
AU2008341671A1 (en) 2009-07-02
US20150342972A1 (en) 2015-12-03
BRPI0821116B8 (pt) 2021-05-25
ATE549313T1 (de) 2012-03-15
US20120041063A2 (en) 2012-02-16
MY164533A (en) 2017-12-29
RU2528393C1 (ru) 2014-09-20
PL2231590T3 (pl) 2012-09-28
CN101903367B (zh) 2015-08-05
ZA201106371B (en) 2013-05-29
RS53140B (en) 2014-06-30
US9187445B2 (en) 2015-11-17
UA104281C2 (ru) 2014-01-27
CN101903337B (zh) 2013-12-18
KR20150076265A (ko) 2015-07-06
BRPI0821116A2 (pt) 2015-08-11
CA2710087A1 (en) 2009-07-02
BRPI0821114B8 (pt) 2021-11-09
AU2008341671B2 (en) 2012-07-26
CA2710087C (en) 2015-06-02
US9827257B2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1115571T1 (el) Νεες ενωσεις και μεθοδοι για θεραπεια
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201171367A1 (ru) Винилиндазолильные соединения
CY1117245T1 (el) Ενωσεις εναντι ογκων
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
NO20081292L (no) Pentasykliske kinaseinhibitorer
SE0301650D0 (sv) Novel compounds
EA200901179A1 (ru) Замещённые тетрагидрохинолины
EA200901180A1 (ru) Производные тетрагидрохинолина и их применение для лечения злокачественного новообразования
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EA200701626A1 (ru) Новые 6-пиридилфенантридины
MX2011006532A (es) Compuestos anticancerigenos.
DK1618116T3 (da) Ruthenium(II)-komplekser til behandling af tumorer
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer